APM
GLUE icon

Avidity Partners Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Avidity Partners Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-300,000
Closed -$6.13M – 97
2021
Q4 		$6.13M Hold
300,000
– – 0.13% 74
2021
Q3 		$6.68M Hold
300,000
– – 0.15% 77
2021
Q2 		$6.81M Buy
+300,000
New +$6.11M 0.18% 83

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Avidity Partners Management's GLUE Position: Q1 2022 in Review

Avidity Partners Management sold out of Monte Rosa Therapeutics (GLUE) in Q1 2022, closing a stake of 300,000 shares — an estimated $6.13M sold.

Avidity Partners Management first reported a position in GLUE in Q2 2021 and held it in 3 quarters. The position peaked at $6.81M in Q2 2021. 52 funds tracked by Wall St. Rank hold GLUE as of Q1 2022.

  • Avidity Partners Management reported no remaining Monte Rosa Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Avidity Partners Management sold 300,000 Monte Rosa Therapeutics shares in Q1 2022, an estimated $6.13M.
  • Avidity Partners Management first reported a position in Monte Rosa Therapeutics in Q2 2021 and held it in 3 quarters.
  • Avidity Partners Management's Monte Rosa Therapeutics position peaked at $6.81M in Q2 2021.
  • 52 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2022.

Based on Avidity Partners Management's 13F filing for Q1 2022, filed 16 May 2022.